Last reviewed · How we verify
GLP-1
At a glance
| Generic name | GLP-1 |
|---|---|
| Modality | Recombinant protein |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Physical Inactivity and Appetite Regulation (NA)
- To Determine Tolerability to Glucagon Infusion in Obese Subjects (PHASE1)
- Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients (PHASE4)
- Tirzepatide in MetALD (PHASE2)
- Effect of a Dietary Supplement on Hormones Involved in Appetite Regulation in Overweight and Obese Adults (NA)
- Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues (EARLY_PHASE1)
- Effect of Prolonged (72 Hour) Glucagon Administration on Energy Expenditure in Healthy Obese Subjects (PHASE1)
- A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GLP-1 CI brief — competitive landscape report
- GLP-1 updates RSS · CI watch RSS